TIDES is coming to San
Diego in 6 weeks! Get a sneak peek of this year's meeting by listening to
exclusive interviews with a few of this year's visionary keynote speakers, who
provide their perspectives on the current state of the oligonucleotide and peptide
industry.
Start planning your team's trip to attend this year's meeting and access 800+
like-minded attendees, 100+ speaker presentations, 70+ exhibitors and 40+
scientific poster presentations. The $200 registration savings deadline
expires on April 10, so secure your seat today:
http://bit.ly/1bxzMyX
Plus, all registered attendees gain immediate access to
Attendee Connect, the partnering tool that
allows you to communicate with fellow attendees before, during and after the
meeting.
Stanley T. Crooke,
M.D., Ph.D. CEO, Isis Pharmaceuticals, Inc.
The progress of technology has yielded new chemistries like
Generation 2.5. How will that improve the potential of antisense
technology?
SC: Second
generation drugs today that we make are significantly better than second
generation [drugs] of just a few years ago in that we get about twice as much
potency and we have much better tolerated drugs and that's a product of advances
in technology. Generation 2.5, we would expect would give us an increase
in potency of about ten-fold...(
Listen to the
full interview)
You say that you are focused on creating the maximum value
for your drugs and technology. Tactically, how are you going that?
SC: I think
focusing on maximum value is the only hope for the industry in general.
With the technology we have at Isis, we have the benefit of very rapidly being
able to take genetic information and convert it to drug. So step one is
to...(
Listen to the full
interview)
Kunwar Shailubhai,
Ph.D., Co-Founder and CSO, Synergy Pharmaceuticals, Inc.
Can you discuss the scientific rationale for developing a
uroguanylin peptide analog to treat functional GI disorders?
KS: Two known
agonists of GCC that are in clinical development are Linactotide, which is an
FDA approved drug and our molecule, plecanatide for functional
disorders/chronic constipation and IBS-C. Now, our molecule – plecanatide – is
an analogue of uroguanylin whereas Linactotide is an analogue of e-coli
enterotoxin. So, I would like to emphasize...(
Listen
to the full interview)
What challenges do you see the peptide industry facing in the next 5 years?
KS: The biggest
challenge when we started working on this compound was to develop large-scale
manufacturing. The next thing that I believe is quite challenging for
peptide drugs is formulation. Formulation should be done in a way that.....(
Listen to the full interview)
The TIDES 2015 Poster
Award
The TIDES 2015 Poster Award, sponsored by AUM LifeTech, Inc.
will recognize TIDES 2015 poster presenters whose poster submission and
research efforts demonstrate exceptional advances and breakthroughs in the
following areas: discovery, pre-clinical and clinical aspects of
oligonucleotide based therapeutic research including but not limited to mRNA
silencing and manipulation, miRNAs, short and long non coding RNAs, exon
skipping, delivery, genome edting, etc.
Three poster award recipients will receive $12,500, $7,500 and $5,000
respectively, in in-kind support/technology/products from AUM LifeTech, Inc.
Through this support, awardees will have access to AUM’s next generation
oligonucleotide technology that can be used to further awardee’s research.
Please refer to
www.aumlifetech.com
for details on AUM’s RNA silencing and manipulation technology. Submissions
from academic and research institutes are especially encouraged, as are
submissions from industry.
To apply for the poster award, you must be a registered
TIDES attendee and submit your poster abstract by April 10, 2015 >> Submit
your poster abstract today:
http://bit.ly/1Iz2PND
Register by Friday,
April 10 and receive a $200 Savings. Your $200 Savings Priority Code =
00DCL3R2B. Register here: http://bit.ly/1bxzMyX
Group rates are available for companies registering 4+
attendees. Call 646-895-7445 to secure
your team's seat today.
Sponsorship/Exhibition
Opportunities: More than 70 leading and emerging oligonucleotide and
peptide companies will be exhibiting or sponsoring this year's TIDES
meeting. Contact Sales Manager Steve Rooney at
srooney@ibcusa.com to secure one of our
few remaining exhibit spaces and/or spotlight speaking opportunities.
Cheers,
The TIDES Team
|
Share this article with your social network, just click below to share now!
|
|
|
